Compare LCTX & TG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | TG |
|---|---|---|
| Founded | 1990 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.6M | 353.3M |
| IPO Year | 1996 | 1994 |
| Metric | LCTX | TG |
|---|---|---|
| Price | $1.25 | $7.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 176.7K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 151.06 |
| EPS | N/A | ★ 0.17 |
| Revenue | $14,556,000.00 | ★ $800,821,000.00 |
| Revenue This Year | $109.40 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $46.74 |
| Revenue Growth | ★ 53.24 | 8.29 |
| 52 Week Low | $0.48 | $6.25 |
| 52 Week High | $2.09 | $10.53 |
| Indicator | LCTX | TG |
|---|---|---|
| Relative Strength Index (RSI) | 31.52 | 30.60 |
| Support Level | $1.14 | $7.30 |
| Resistance Level | $1.31 | $8.04 |
| Average True Range (ATR) | 0.08 | 0.58 |
| MACD | -0.02 | -0.29 |
| Stochastic Oscillator | 10.78 | 0.32 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.